News

Enzene Has Launched NeX™ — a Turnkey Biologics Manufacturing Model That Lets Governments and Institutions Build World-Class Biopharma Capability Without the Conventional Capex

By Mustafa Shariff, Editor in Chief · August 10,2026 · 2 min read

Summary

• Enzene Launches NeX™: Turnkey Biologics Manufacturing Platform Enabling Local Biopharma Production Without Conventional Capex Barriers
• Enzene Biosciences launched NeX™ on August 4, 2026 — an end-to-end biologics manufacturing partnership model enabling governments and institutions to build world-class biomanufacturing capability via Enzene's proven FCCM continuous platform, without conventional fed-batch facility investment.

"The challenge for most governments and institutions is not the desire to manufacture biologics locally — it is the prohibitive upfront investment that conventional fed-batch bioreactor facilities require. NeX changes this equation. By combining our proven FCCM platform with a full end-to-end partnership model — facility design, technology transfer, IP licensing, training, and ongoing production support — we enable any qualified partner to build world-class biologics manufacturing where they need it, without the traditional barriers to entry."

Enzene Biosciences, the Pune-based continuous innovation development and manufacturing organisation (CIDMO), launched NeX™ on August 4, 2026 — a transformative end-to-end partnership model designed to enable governments, national health institutions, and biopharmaceutical companies to establish world-class biomanufacturing capabilities in their own geographies, at the scale and cost point they need, without the prohibitive upfront capital investment that conventional biological manufacturing facilities require.
The NeX platform leverages Enzene's proven EnzeneX Fully-Connected Continuous Manufacturing (FCCM) platform — a proprietary continuous biomanufacturing technology that operates bioreactors in a continuous, connected mode rather than in discrete batch cycles. Continuous biomanufacturing is fundamentally different from the fed-batch manufacturing that characterises conventional biologics production: rather than filling a bioreactor, growing cells to maximum density, harvesting the entire batch, cleaning, and starting again — continuous manufacturing maintains a steady-state of cell culture and product production, with continuous feeding and continuous product removal, producing a constant stream of biologic drug substance rather than discrete batches.
Why Continuous Manufacturing Changes the Capex Equation
The commercial significance of continuous biomanufacturing for emerging markets, smaller institutions, and governments building local biologics production capacity is specifically in the capital intensity reduction it enables. A conventional fed-batch biologics facility — the kind that major global biopharmaceutical companies operate for commercial production of monoclonal antibodies, biosimilars, and other biologics — requires bioreactor vessels measured in tens of thousands of litres, associated downstream processing equipment of equivalent scale, and total facility capital investments that routinely exceed $100-500 million for commercial-scale operations.
Enzene's FCCM platform achieves equivalent or superior productivity at dramatically smaller bioreactor volumes — because continuous operation maintains cells at high density and high productivity without the non-productive periods of batch growth, harvest, and cleaning that reduce the effective output of fed-batch systems. A continuous bioreactor of 1,000 litres can match or exceed the annual production output of a fed-batch bioreactor of 10,000-20,000 litres when operated continuously at high efficiency. This tenfold-plus productivity advantage translates directly into proportionally smaller facility footprint, equipment cost, and capital investment.
What NeX Provides
The NeX programme goes beyond the provision of Enzene's FCCM technology licence — it is a full end-to-end partnership model. Enzene coordinates the complete set-up and launch of a NeX partner's biomanufacturing facility, providing support across facility design and construction, technology transfer of the FCCM platform, intellectual property licensing for the EnzeneX continuous manufacturing process, training of the partner's technical workforce, regulatory support for submissions to local and international regulatory authorities, and ongoing production guidance during initial commercial operation.
This comprehensive partnership model addresses the most significant barrier that governments and institutions face beyond the capital cost: the technical knowledge and regulatory expertise required to actually operate a biomanufacturing facility to the quality standards that regulatory authorities require. A government that builds a biological manufacturing facility without the technical expertise to run it compliantly has spent capital without achieving supply security — NeX explicitly addresses this by embedding Enzene's expertise into the partner's operation from design through ongoing production.
The India Biologics Manufacturing Context
The Enzene NeX launch arrives in the middle of a period of intense activity in India's biologics manufacturing capacity building: Aurobindo's TheraNym biologics CMO inauguration (covered August 3 edition), NITI Aayog's Bioeconomy Roadmap 2035 and Rs 50,000 crore BioEconomy Growth Fund (covered July 20 edition), and Biopharma SHAKTI's 100 biologics by 2047 target (covered June 18 edition) all reflect the institutional commitment to building India's biologics manufacturing ecosystem. Enzene's NeX model offers a distinctive approach: rather than a conventional fee-for-service CDMO relationship, it enables partners to build their own manufacturing capability in their own geography, with Enzene's intellectual property and technical expertise embedded.
BHC Perspective
At Bengaluru Health Community, Enzene's NeX launch is a bioprocessing innovation story that goes beyond India's domestic biologics ambitions to address a global health equity challenge: the concentration of biologic manufacturing in a small number of high-income country facilities creates supply chain fragility and affordability barriers for patients in emerging markets. NeX, by making continuous biomanufacturing technology transferable to any geography, directly addresses this structural inequity. For BHC founders in biologics, bioprocessing, or healthcare supply chain — Enzene's FCCM platform and NeX model define one answer to the question of how biologics access can be democratised globally.
Frequently Asked Questions
Q: What is Enzene's NeX™?
A: An end-to-end biologics manufacturing partnership model launched August 4, 2026, enabling governments, institutions, and biopharma companies to establish local biomanufacturing capability using Enzene's proven FCCM (Fully-Connected Continuous Manufacturing) platform — including facility design, technology transfer, IP licensing, regulatory support, and ongoing production guidance.
Q: What is Continuous Manufacturing (FCCM) and why does it reduce capex?
A: Continuous biomanufacturing maintains steady-state cell culture and product production without discrete batch cycles, achieving equivalent productivity at dramatically smaller bioreactor volumes (potentially 10x higher output per litre vs fed-batch). This translates into proportionally smaller facility footprint, equipment cost, and total capital investment — making biologics manufacturing accessible to partners without conventional facility budgets.
Q: What does NeX include?
A: Full coordination of set-up and launch: facility design and construction support, technology transfer of FCCM platform, IP licensing for EnzeneX continuous manufacturing process, workforce training, regulatory support, and ongoing production guidance during initial commercial operation.